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Abstract The subcellular localization of natural and engineered 
forms of the chicken thyroid hormone receptor (cTRoc) is 
dependent on amino acids encoded in the N-terminal region. 
The full length receptor protein, cTRa-p46, was found to localize 
exclusively to the nucleus, whereas the N-terminally shorter 
variant, cTRa-p40, localizes to both the nucleus and the 
cytoplasm. The exclusive nuclear localization of cTRoc-p46 is 
dependent on the presence of the first 11 N-terminal amino acids, 
but independent of the phosphorylation of the serine at position 
12. Our data identify a novel role for an N-terminal domain of 
the full length thyroid hormone receptor. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Steroid and thyroid hormone receptors function as ligand 
dependent transcription factors through binding to enhancer 
sequences that regulate transcription of target genes [1^1]. 
These receptors have functional domains in common : a ligand 
binding domain (LBD), a DNA binding domain (DBD), and 
activation function domain(s) (for review see [5]). The recep-
tors for the steroids, i.e. glucocorticoid, progesterone and 
mineral corticoid, interact with cytosolic heat shock proteins 
which dissociate from the receptor in presence of hormone 
ligand [6]. Heat shock proteins are, however, not associated 
with the other subgroup of hormone receptors such as the 
thyroid hormone receptor (TR), the retinoid receptors and 
the vitamin D3 receptor [7]. Unlike the other steroid recep-
tors, the estrogen receptor (ER) does not require hormone for 
nuclear transport [8,9]. The TR as well as the ER are con-
stitutively localized to the nucleus and are thus independent of 
ligand for nuclear localization [10]. 
The nuclear localization of proteins is mediated through a 
conserved nuclear localization signal (NLS) that allows them 
to bind transporter molecules in the cytoplasm or at the nu-
clear pore [11,12]. Consensus NLS sequences have been de-
fined, and consist of a short stretch of arginine and lysine 
residues [13,14]. The NLS sequences are sufficient for confer-
ring a nuclear localization on most proteins; however, the 
glucocorticoid receptor (GR) needs additional signals, i.e. 
hormone binding and phosphorylation [15]. Thus, the mech-
anism by which nuclear transcription factors expose their 
NLS sequences may involve modifications of the receptors 
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such as phosphorylation, dephosphorylation or binding of 
ligand [16,17]. 
The chicken TRoc receptor mRNA produces two proteins 
due to two translational initiation sites in the 5' untranslated 
region. A 46 kDa protein is made when the first AUG is used 
(cTRoc-p46), whereas initiation at the second AUG yields a 
protein of 40 kDa (cTRoc-p40), 36 amino acids shorter. Both 
proteins bind Тз, heterodimerize with the retinoic X receptor 
(RXR), and transactivate target genes. The N-terminal region 
(amino acids 1-36) of the cTRoc-p46 contain an N-terminal 
activating function domain (AF-1) [18], and harbors two 
phosphorylation sites, one at serine residue 12 and another 
at serine 28/29. The serine residue 12 is a phosphorylation 
site for casein kinase II (CKII) [19] whereas the serine residues 
28/29 are defined as a protein kinase A (PKA) phosphoryla-
tion site [20]. The aforementioned N-terminal features are 
absent in cTRoc-p40. Both receptor forms have been found 
in vivo [21]. 
To elucidate the role of the sequences outside the NLS in 
subcellular localization we have studied the localization of 
naturally occurring and engineered forms of cTRoc. Our 
data show that exclusive nuclear localization of TR is depend-
ent on a short N-terminal domain consisting of 11 amino 
acids. The difference in partitioning of the two N-terminal 
variant receptors indicates that the two isoforms may operate 
in part through distinct mechanisms. 
2. Materials and methods 
2.1. Expression vectors 
The pSG5 vector was used for expression of receptor proteins in 
transfected cells and in Xenopus oocytes. To express TRa-p46 and 
cTRa-p40 individually, we used two plasmids expressing one isoform 
only. The AUG for the smaller protein was replaced with a codon for 
leucine allowing expressing of TRa-p46, and to express the cTRa-p40 
protein the first initiation codon of the cDNA was removed [22]. The 
receptor plasmids expressing cTRa, TRßO, Р75кч;-»-егЬА o r psG-V3 
have been described [23-27]. A plasmid containing part of the retro-
viral gag region (nucleotides 1597-2243) of pSFCVneo [28] fused to 
the full length cDNA of cTRoc (pAXAgagTR) was subcloned into the 
EcoRl sites of pSG5 (gagTRa). The cTRa-A12 mutant [19] receptor 
fragment was taken from the plasmid pNEO-MAV-c-erbA A12 [29] 
and inserted into EcoRl sites of pSG5. 
2.2. Cells and transfections 
5x IO4 JEG-3 human choriocarcinoma cells [25] were seeded onto 
12 mm coverslips in 24 well plates or into tissue culture chambers 
(Nunc) containing Dulbecco's medium with 8% fetal calf serum. 
The medium was changed the following day and transfections were 
performed as described [30]. Cells used for immunocytochemistry were 
transfected with 0.03-3 μg of receptor plasmid DNA. 7X104 QT6 
cells [28] were seeded in 6 well plates and cells were transfected the 
next day with 500 ng of receptor plasmid per well. Twenty-four hours 
post transfection the cells were harvested and total extract was taken 
up in 20 μΐ 250 mM Tris pH 7.8. 5 μΐ of extract was loaded on a 10% 
SDS gel for Western blot analysis. 
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2.3. Immunocytochemistry 
Forty-eight hours after transfection cells were washed with PBS and 
treated with serial dilutions of methanol followed by fixation in 4% 
paraformaldehyde in PBS at +4°C for 2-16 h. After three washes with 
PBS, the coverslips were transferred to a rack with the cell side up. 
Cells were incubated with 0.3% normal goat serum (NGS), 0.2% bo-
vine serum albumin (BSA) in PBS for 10 min; NGS in BSA/ 
PBS+0.3% Triton X-100 for 5 min followed by 1% H 2 0 2 in BSA/ 
PBS for 5 min. After three washes the cells were incubated with 
primary antibody in a humidified chamber at +4°C overnight. A 
rabbit polyclonal cTRß antiserum recognizing cTRa, cTRß and 
P75gag-v-erbA p5] and a control antibody recognizing snRNP [31] 
were used at dilutions of 1:200 and 1:10 respectively. After three 
washes in PBS cells were incubated with biotin-coupled goat anti-
rabbit IgG or anti-mouse IgM secondary antibody (Vectastain Elite 
ABC kit, Vector Laboratories, Burlingame, CA) for 45 min. Follow-
ing washes, the cells were incubated with ABC reagent (avidin con-
jugated to horseradish peroxidase) for 45 min, and the immunoreac-
tion was visualized by adding diaminobenzidine (DAB) chromogen 
substrate (Dako Corporation, Carpinteria, CA) in 0.1% Η 2 0 2 . The 
coverslips were washed in H 2 0 and then dipped in ethanol followed 
by mounting onto glass slides for microscopy. Stained cells were pho-
tographed with 64 ASA Tungsten color film in microscope with a 
100 X objective. Slides were scanned into a computer and the picture 
panels were designed using Adobe Photoshop. 
2.4. Sequence homologies and protein secondary structure prediction 
Homology searches were done in the EMBL and SwissProt data 
banks. The secondary structure of the first 50 amino acids of cTRa-
p46 was predicted using the Predict Protein program, EMBL. 
2.5. Oocyte injection 
50-250 ng receptor DNA in pSG5 was injected into Xenopus eggs. 
The next day the oocyte nucleus was extracted in 5 μΐ and applied in a 
10% SDS gel in parallel with the extract from the cytoplasmic fraction 
taken up in 20 μΐ. Proteins were detected with anti-TRa [25] in West-
ern blot. 
2.6. Western blot 
Total extracts from QT6 cells or from single oocytes were loaded 
onto 10% SDS-PAGE gels. Gels were run with 100 V for 2 h and 
proteins were then transferred to nitrocellulose filters (PVDF Transfer 
Membrane, DuPont) using semi-dry transfer. After 1 h in blocking 
buffer, the filter was incubated with the primary antibody on a rock-
ing platform in +4°C overnight. A washing step was followed by 
adding the secondary antibody for 30 min at room temperature. After 
subsequent washing steps the filter was subjected to ECL treatment 
(Amersham) followed by exposure to X-ray films (Kodak). 
3. Results 
3.1. Cytoplasmic and nuclear localization of cTRa 
As a result of utilizing different A U G codons in the 5' 
untranslated region, the m R N A for c T R a yields two different 
A/B 
|p p 
[ 
[ 
1* P 
K W W W N P P 
1 1 
1 1 
1 1 
1 1 
1 1 
l \ \ \ \ W \ 4 p 1 1 1 
k \ \ \ \ \ \ 4 1 . P . • · ι · · · · 1 1 
cTRa - p46 
cTRa - p40 
cTRßO 
cTRa-A12 
gagTRa 
V3 
P75gag-v-erbA 
gag DBD LBD 
Fig. 1. Thyroid hormone receptors. The cTRcc-p46 and cTRa-p40 
isoforms are naturally occurring receptors. The shorter isoform 
lacks the first 36 amino acid residues of cTRa-p46. Variant cTRa 
receptors are: cTRa-A12 containing a serine to alanine mutation at 
residue 12 of cTRa-p46; gagTRa, containing a portion of the retro-
viral gag gene fused to cTRa-p46; P75gag-v-erbA5 the oncogenic ho-
mologue of cTRa, which lacks the 12 first amino acids of the N-ter-
minus as well as the last nine amino acids in the C-terminus and 
also contains 13 amino acid substitutions; V3, containing the 
P75gag-v-erbA N - t e r m m a i gag domain fused to cTRa-p46 at residue 
13. cTRß has two N-terminal isoforms and shown here is the short 
isoform, cTRßO. White colored boxes indicate the ligand binding 
domain (LBD) and the DNA binding domain (DBD). The N-termi-
nus is indicated with light shading. The positions of point mutations 
(black dots), phosphorylation sites (P) and mutated phosphorylated 
site (*) are indicated. 
receptor proteins, cTRoc-p46 and cTRa-p40 (see Fig. 1). The 
latter protein is more abundant in vivo [21]. Our initial im-
munocytochemical analyses demonstrated that cells t rans-
fected with a c D N A allowing both receptors to be expressed 
contained receptor protein both in the nucleus and in the 
cytoplasm (not shown). To determine the identity of the cy-
toplasmic receptor, we transfected cells with plasmids express-
ing either the long or the short isoform [22]. Subsequent im-
munocytochemical analysis show that the cTRa-p46 isoform 
localized exclusively to the nucleus (Fig. 2a), whereas cTRoe-
p40 partit ioned to both the nucleus and the cytoplasm (Fig. 
2b). This localization pattern was fully reproduced in all cells 
studied (Table 1). 
To verify the above results with another experimental ap-
proach, we injected 8-10 Xenopus oocytes with constructs ex-
pressing cTRcc-p40 or cTRoc-p46. A Western blot analysis of 
the nuclear and cytoplasmic fractions from single oocytes is 
shown in Fig. 3. The results demonstrate that close to 100% of 
Table 1 
cTRa and variant receptor subcellular distribution 
Receptor 
TRa-p46 
TRa-p40 
TRßO 
p75gag-v-erbA 
V3 
gagTR 
TRa-p46 
TRa-A12 
Cells with 
exclusive nuclear 
localization 
29 
4 
5 
0 
3 
28 
98 
77 
cytoplasmic and 
nuclear localization 
1 
29 
27 
30 
24 
2 
2 
23 
Nur 
30 
33 
32 
30 
27 
30 
100 
100 
mber of cells counted % cells with exclusive nuclear localization 
97 
12 
16 
0 
11 
93 
77 
Cells were transfected with cTRa variant expression plasmids and stained cells were counted. Numbers are averages of three independent experi-
ments. 
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Fig. 2. Subcellular localization of cTR isoforms as shown by immunocytochemistry. Images of representative cells from the experiment quanti-
fied in Table 1 are shown. Transfected JEG cells were grown in the presence (a,b,c) or absence (d,e,f) of thyroid hormone. Cells were trans-
fected with cTRa-p46 cDNA (a and d), with cTRa-p40 cDNA (b and e), or with cTRßO cDNA (c and f). Size bar: 10 μτα. 
cTRa-p46 was found in the nucleus, whereas the nuclear to 
cytoplasmic ratio in the oocyte expressing cTRa-p40 was ap-
proximately 50%. Similar results were obtained with the re-
maining oocytes, and no signal was detected in extracts from 
oocytes injected with an empty plasmid vector. 
The cTRßO isoform (Fig. 1) is encoded by a distinct gene 
and has an overall high homology with cTRa-p40. However, 
their 14 amino acids preceding these DBDs are identical [32]. 
Our analyses show that cTRßO has nuclear translocation 
properties similar to those of cTRa-p40, since it partitioned 
to both cellular compartments (Fig. 2c). We conclude that 
amino acids in the N-terminal region of cTRa-p46 but absent 
in cTRcc-p40 and cTRßO confer the exclusive nuclear local-
ization. 
To test if receptor protein localization was an effect of the 
amount of DNA added in transfection and if increased 
amounts of receptor plasmid could saturate the expression 
in the nucleus, transfections were done with increasing 
amounts of DNA, ranging from 30 ng to 3 μg per well. The 
results showed that increased amounts of plasmid did not 
alter the distribution of the receptor (not shown). This sug-
gests that the cells were not saturated with receptor protein at 
the highest DNA plasmid concentrations used, and that leak-
age from the nuclear compartment to the cytosol was unlikely. 
The above experiments were done in media with normal 
fetal calf serum. Experiments done in media depleted of thy-
roid hormone showed that absence of ligand does not affect 
the localization of TRs in the cell (Fig. 2d,e,f). 
Oocyte 1 Oocyte 2 
Fig. 3. Localization of cTRa isoforms in single microinjected Xeno-
pus oocytes. 8-10 oocytes were injected with plasmid expressing the 
indicated cTRa isoform. The nuclear (N) and cytoplasmic (C) frac-
tions from single, representative, oocytes were analyzed by Western 
blot. 
3.2. Subcellular localization of alternative forms of TRs 
The viral homologue of cTRa, р~]5^е-^-етЪА^ differs from 
cTRa-p46 in a number of ways [23]. As a consequence of an 
N-terminal fusion with retroviral gag sequences, P75 lacks the 
first 12 amino acids of cTRoc-p46 (Fig. 1). In addition, the 
viral protein lacks 9 amino acids close to the C-terminus and 
has sustained 13 amino acids distributed along the molecule. 
P75gag-v-erbA n a s ь е е п shown to be localized both in the nu-
cleus and in the cytoplasm [33]. To establish how the struc-
tural changes in the p75sag-v-erbA determine the localization 
of the receptor we first tested p75gag-v-erbA by immunocyto-
chemistry. Fig. 4a shows that the viral protein localizes prom-
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Fig. 4. Subcellular localization of the cTR variants P75gag 
chemistry. Size bar: 10 μηι. 
(a), V3 (b) and gagTRa (c). Transfected cells were analyzed by immunocyto-
inently to the cytoplasm, although nuclear staining was evi-
dent as well. This observation is in agreement with the bio-
chemical results obtained previously [33]. To further study the 
influence of the N-terminal deletion, we used a chimeric re-
ceptor V3 (Fig. 1) which contains the gag region of 
P75gag-v-erbA f u s e d t 0 c x R a . p 4 6 a t residue 13 as in 
p75gag-v-erbA p7]. Cells transfected with this construct con-
tained immunoreactive protein in both the cytoplasm and the 
nucleus (Fig. 4b). The observation that P75gag-v-erbA a n d t h e 
V3 receptor partitioned to both compartments (Table 1) sug-
gests that this property is due to the lack of the first 12 amino 
acid residues present in cTRot-p46, or to the presence of gag 
sequences. To exclude that the gag sequences did not influence 
the subcellular localization we transfected a construct express-
ing the full length cTRoc-p46 fused to gag sequences. The 
resulting gagTRa protein was found exclusively in the nucleus 
(Fig. 4c), suggesting that a fusion with gag does not influence 
nuclear localization of cTRa-p46, and that the first 12 amino 
acids of TR are critical for exclusive nuclear localization. 
3.3. Serine to alanine mutation of residue 12 in TRa-p46 
The observation that all the receptor proteins that lack the 
first 12 amino acids (cTRa-p40, cTRßO, Р758ад-^-еЛА a n d V 3 ) 
localized to both cellular compartments led us to suspect that 
the serine CKII site at position 12 is necessary for complete 
nuclear transfer. To test this we used a plasmid expressing a 
mutant receptor that contains an alanine residue at the site of 
serine 12 (cTRoc-A12). Subsequent analysis showed that most 
of the cells expressing cTRoc-A12 localized to the nucleus and 
Fig. 5. Detection of intact receptors in transfected cells. Protein ex-
tracts were separated on SDS-PAGE, and analyzed by Western 
blot. The control lane (C) contains extract from cells transfected 
with an empty expression vector. cTRa-p46 and cTRa-A12 have 
molecular weights of 46 kDa and the weight of V3 is 75 kDa. 
that a minor portion of the cells expressed this receptor in 
both compartments (Table 1). This demonstrates that a serine 
to alanine exchange at residue 12 in cTRa-p46 does not sig-
nificantly alter the expression pattern in most cells, and that 
the serine in the CKII phosphorylation site is not essential for 
exclusive nuclear localization of the receptor. 
To verify the integrity of the receptor proteins we per-
formed Western blot analysis of the whole cell extracts of cells 
transfected with vectors expressing cTRoc-p46, cTRoc-A12 or 
V3. Fig. 5 shows that all three receptor proteins were intact. 
4. Discussion 
Previous reports have identified an important nuclear trans-
location sequence signal in the 'hinge' domain, C-terminal to 
the DNA binding region [34]. However, the data concerning 
the subcellular localization of cTRoc and its oncogenic variant 
P75gag-v-erbA h a v e b e e n c o n f l i c t i n g [23,33]. We therefore elu-
cidated further the requirements for subcellular localization of 
thyroid hormone receptors and their variants. Our results 
show that the ultimate N-terminal domain contains a novel 
domain that confers exclusive nuclear localization (ENL) to 
cTRa-p46, and that it is absent in shorter TR isoforms and in 
the oncoprotein F75g«g-v-erbA_ 
Proteins that are transported to the nucleus usually contain 
a basic stretch of amino acids referred to as the nuclear local-
ization signal, NLS. While the prototype NLS [14] consists of 
five basic amino acids, the glucocorticoid receptor has two 
such signals, one in the hinge region (region D) and one in 
the ligand binding domain [15]. In contrast, the hinge region 
of TR contains a single NLS that was reported to be sufficient 
for exclusive nuclear localization since it was transferable to 
an unrelated cytoplasmic protein [35]. Our data indicate that 
the ENL complements the function of NLS, since it confers 
exclusive nuclear localization to an intact, NLS containing 
receptor. 
In cTRoc the long and the short isoforms are identical in 
their amino acid sequence except for their N-terminal regions. 
Sequence alignment of N-terminal regions of TRa from dif-
ferent species shows that the region is considerably conserved 
(Fig. 6). Two characteristic domains are located within the 
first 36 amino acid residues. The first one, containing mainly 
acid acids at position 1-16, encompasses the first 11 amino 
acids required for exclusive nuclear localization and the phos-
phorylation site at position 12. This region may form a loop 
that is involved in forming binding sites, possibly to aid in 
interaction with other proteins [18], i.e. basal transcription 
factors or factors that enhance nuclear localization. The sec-
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Fig. 6. Alignment of N-terminal sequences in TRa from different species. The acidic and basic regions are boxed. Residues 21-30 are essential 
for transcriptional activation function 1 [18], indicated by a solid bar. The PKA and CKII phosphorylation sites are indicated. 
ond region, amino acids 21-30, is basic and constitutes the 
AF-1 domain [18]. The PICA site at position 28/29 is con-
served only in receptors from birds and cold-blooded verte-
brates. It is tempting to speculate that cTRa-p40 contains, in 
addition to the NLS, a nuclear export signal, whereas cTRoi-
p46 in addition contains the ENL that counteracts the export. 
That TR isoforms, lacking N-terminal amino acid residues, 
localize to both the nucleus and the cytoplasm shows that 
nuclear import is independent of phosphorylation in the N-
terminus, a conclusion supported by our observation that the 
serine 12 phosphorylation site is dispensable for subcellular 
localization. We cannot, however, easily determine the reason 
for the cytoplasmic localization, although several possibilities 
can be suggested. Other post-translational modifications could 
be a prerequisite for efficient nuclear import, or the lack of 
such modifications could result in poor nuclear retention [36]. 
Such a modification that localizes a variant receptor to the 
cytoplasm may cause an inefficient import through the nuclear 
pore leaving a portion of receptors in the cytoplasm; or may 
result in an accelerated export of the receptors. As some of the 
variant TRs that lack the first amino acid residues from 
cTRot-p46 are large fusion proteins, we exclude the possibility 
that the cytoplasmic localization is a result of diffusion caused 
by a smaller size. Recently, Dobbelstein et al. demonstrated 
that two adenovirus proteins modify nuclear export and im-
port [36]. Intrinsic signals that direct a protein into the cyto-
plasm [17] have not been found in the TR molecule; more-
over, our experiments suggest that the energy dependent 
nuclear shuttling mechanism described for the progesterone 
receptor (PR) [37,38] is not recruited by cTRoc-p46 (data 
not shown). 
The biological significance of expressing the two N-terminal 
variants cTRa-p46 and cTRa-p40 in a cell is unclear. In the 
PR, the N-terminal region is important for tissue target gene 
specificity [39]. A short N-terminal isoform of PR, expressed 
in most cells, activates transcription of target genes in some 
cell types but differs from the full length PR in its function as 
a repressor in other tissue types [40]. The TR p40 isoform is 
abundantly expressed in chicken embryonic erythroid cells 
[21], and it functions as a T3 dependent transcription factor 
via thyroid hormone receptor response elements [22,41]. Had-
zik and collaborators have shown that cTRa-p46 in HeLa 
cells enhances transcription more efficiently than cTRoc-p40 
due to its N-terminal AF-1 domain [18]. It is thus likely 
that the transactivation domain unique to cTRoc-p46 strongly 
activates or represses certain target genes, perhaps in a tissue 
specific manner. The short isoforms of either TRa or TRß 
would accordingly have a lower transactivation potential 
and perhaps fewer gene specific activities. Another alternative 
is provided by reports that suggest a cytoplasmic or mito-
chondrial function for thyroid hormones [42,43]. 
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